TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00368771

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: IBS Educational Training
Description: Those assigned to this group will be given educational materials about IBS and will discuss the reading material with the therapist. The reading topics include information on gut disorders, anatomy and physiology of the gut, assessment procedures, and how to manage IBS symptoms. Sessions will also consist of weekly reviews of daily records and IBS symptoms. The goal of this intervention is to provide educational training about IBS.
Study: NCT01926210

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: controlled ovarian stimulation
Description: After fully downregulation by using short-acting GnRH agonist, 300 IU/d recombinant FSH is administrated for 5 days, then the dose is adjusted according to ovarian response.
Study: NCT04521868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulforaphane
Description: Sulforaphane is a compound that can be extracted from broccoli, Brussel sprouts, cabbage, and other cruciferous plants.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo is made of starch
Study: NCT01963611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plovamer acetate 0.5 milligram (mg)
Description: Plovamer acetate was administered at a dose of 0.5 mg as weekly subcutaneous injection for 40 weeks up to a maximum of 14 months.
Study: NCT03933865

Intervention type: DRUG
Group type: OTHER
Intervention: HYDROmorphone Injectable Solution
Description: Hydromorphone will be given via intramuscular injection (8 mg)

Intervention type: DRUG
Group type: OTHER
Intervention: Ketamine
Description: Ketamine will be given via intramuscular injection (0.1, 0.2 or 0.4 mg/kg)

Intervention type: DRUG
Group type: OTHER
Intervention: Placebos
Description: Placebo will be normal saline solution given via intramuscular injection.
Study: NCT00971386

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Slow breathing
Description: The subjects will be given instructions in slow breathing at a rate of 6 to 10 breaths per minute and asked to practice it for some time. Hemodynamic measurements would be repeated before, during and after the trial of slow breathing. A Noninvasive Cardiac Output Monitor will be used. It uses a technology called impedance to measure cardiac output and other hemodynamic parameters by the passage of electric currents through the thorax. This device uses four electrode stickers applied to the thorax and the neck.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Slow breathing
Description: The subjects will be given instructions in slow breathing at a rate of 6 to 10 breaths per minute and asked to practice it for some time. Hemodynamic measurements would be repeated before, during and after the trial of slow breathing. A Noninvasive Cardiac Output Monitor will be used. It uses a technology called impedance to measure cardiac output and other hemodynamic parameters by the passage of electric currents through the thorax. This device uses four electrode stickers applied to the thorax and the neck.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Slow breathing
Description: The subjects will be given instructions in slow breathing at a rate of 6 to 10 breaths per minute and asked to practice it for some time. Hemodynamic measurements would be repeated before, during and after the trial of slow breathing. A Noninvasive Cardiac Output Monitor will be used. It uses a technology called impedance to measure cardiac output and other hemodynamic parameters by the passage of electric currents through the thorax. This device uses four electrode stickers applied to the thorax and the neck.
Study: NCT02751840

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: 200 mg of caffeine capsule before RMR measurement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: 200 mg of caffeine capsule before RMR measurement

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Caffeine
Description: 200 mg of caffeine capsule before RMR measurement

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Caffeine
Description: 200 mg of caffeine capsule before RMR measurement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsule (starch) before RMR measurement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsule (starch) before RMR measurement

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule (starch) before RMR measurement

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule (starch) before RMR measurement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coffee
Description: 9 grams of black coffee in boiling water consumed before RMR measurement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coffee
Description: 9 grams of black coffee in boiling water consumed before RMR measurement

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Coffee
Description: 9 grams of black coffee in boiling water consumed before RMR measurement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decaffeinated
Description: 9 grams of decaffeinated black coffee in boiling water consumed before RMR measurement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decaffeinated
Description: 9 grams of decaffeinated black coffee in boiling water consumed before RMR measurement

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Decaffeinated
Description: 9 grams of decaffeinated black coffee in boiling water consumed before RMR measurement
Study: NCT04747925

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mulligan two leg rotation core muscle strengthning exercises
Description: Group A :is receiving moist heat for the hamstrings muscles prior the Mulligan Two leg rotation technique for 10mins.Hold the position for 30 seconds, relax for 1 minute. Reps are given 3 repetitions. And 3 Sets at each session .core muscle strenthening exercises for back extensors and abdominals i.e Bridge curls ,table top ,abdominal crunches,back extension with arms supporting, is being performed. Position is being held for about 10 seconds and each exercise are performed with 10 repititions. Patient is being relaxed for 3 seconds between repetitions and 60 second rest between each exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mulligan bent leg raise technique, core muscle strengthning exercises
Description: Group B is receiving moist heat for the hamstrings muscles prior the Mulligan Bent leg raise technique for 10 minutes. Hold the position for 30 seconds, relax for 1 minute. Reps are 3 repetitions. And 3 Sets at each session .Subject is being receive 2 weeks protocol. core muscle strenthening exercises for back extensors and abdominals i.e Bridge curls ,table top ,abdominal crunches,back extension with arms supporting, are being performed. Position is held for about 10 seconds and each exercise is performed with 10 repititions. Patient is being relaxed for 3 seconds between repetitions and 60 second rest between each exercise
Study: NCT01052298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (Cipro inhale, BAYQ3939)
Description: 32.5 mg ciprofloxacin betaine corresponding to 50 mg Ciprofloxacin Pulmosphere inhalation powder will be given as an initial single dose application on day 00d.During the multiple dose phase (day 02d to 10d) the same dose will be given twice daily (bid) with a concluding single dose on 11d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (Cipro inhale, BAYQ3939)
Description: 32.5 mg ciprofloxacin betaine corresponding to 50 mg Ciprofloxacin Pulmosphere inhalation powder will be given as an initial single dose application on day 00d.During the multiple dose phase (day 02d to 10d) the same dose will be given three times daily (tid) with a concluding single dose on 11d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (Cipro inhale, BAYQ3939)
Description: 48.75 mg ciprofloxacin betaine corresponding to 75 mg Ciprofloxacin Pulmosphere inhalation powder will be given as an initial single dose application on day 00d.During the multiple dose phase (day 02d to 10d) the same dose will be given twice daily (bid) with a concluding single dose on 11d.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo inhalation powder will be given as an initial single dose inhalation on 00d.During the multiple dose phase placebo will be given twice/three-times daily with a concluding single dose on day 11d.
Study: NCT03602872

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human allogeneic mesenchymal bone marrow derived stem cells
Description: Intraarticular administration of 20x10\^6 MSCs

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human allogeneic mesenchymal bone marrow derived stem cells
Description: Intraarticular administration of 20x10\^6 MSCs

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human allogeneic mesenchymal bone marrow derived stem cells
Description: Intraarticular administration of 20x10\^6 MSCs
Study: NCT01816243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTS-Fentanyl
Description: Transdermal Therapeutic System (TTS)-fentanyl patches releasing fentanyl in the range of 12.5 to 100 microgram per hour (mcg/hr) rate. The initial dose of fentanyl TTS will be calculated based on each participant's opioid requirement. Patches will be usually replaced every 72 hours. Doses will be escalated in steps of 25 mcg/hr, if pain cannot be controlled. The study duration will be 30 days after first patch application.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Participants will be allowed the use of oral morphine syrup for the duration of TTS-fentanyl treatment to enable appropriate dose titration. It is expected that most of the participants will be titrated to an appropriate dose of TTS-fentanyl within 1 week.
Study: NCT00280761

Intervention type: DRUG
Intervention: capecitabine
Description: Capecitabine administration (where deemed appropriate by the treating medical oncologist) will commence on the second day of radiotherapy after the 24-hour biopsy has been performed. Dosing will be per current standard of care at the discretion of the treating Medical, Radiation and Surgical Oncologist

Intervention type: DRUG
Intervention: 5-fluorouracil
Description: Administration of 5-fluorouracil (where deemed appropriate by the treating medical oncologist) will commence on the second day of radiotherapy after the 24-hour biopsy has been performed. Dosing and dose modification will be per current standard of care at the discretion of the treating Medical, Radiation and Surgical Oncologist.

Intervention type: PROCEDURE
Intervention: Surgical Resection
Description: Surgery will occur approximately 2-6 weeks after chemoradiation depending on clinical factors (i.e. resectability, presence or absence of metastatic disease).

Intervention type: RADIATION
Intervention: Radiation therapy
Description: Dosing and dose modification will be per current standard of care at the discretion of the treating Radiation Oncologist.
Study: NCT04336761

Intervention type: DIAGNOSTIC_TEST
Intervention: nasopharyngeal swab
Description: Data collection and nasopharyngeal swab
Study: NCT03252483

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bundled HCV/HIV Screening
Description: Participants were randomized to a bundled HIV/HCV test group (intervention) to evaluate whether integrating HIV and HCV rapid screening would adversely impact HIV test acceptance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HIV Screening
Description: Participants were randomized to an HIV-only screening group as a control comparator.
Study: NCT01459250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGO178C
Study: NCT02061865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN2176-3
Study: NCT02308683

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Moringa oleifera
Description: 12 weeks supplementation
Study: NCT01524354

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: maintenance of anesthesia
Description: intraoperative maintenance of anesthesia with propofol under control of cerebral state index at 40-60 points

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: maintenance of anesthesia
Description: intraoperative maintenance of anesthesia with propofol according to recommendations of the manufacturer
Study: NCT03441178

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ENSEAL X1
Description: ENSEAL X1 is used for transecting and sealing vessels according to instructions for use.
Study: NCT01918670

Intervention type: PROCEDURE
Intervention: catheter ablation of atrial fibrillation
Description: electric pulmonary vein disconnection

Intervention type: PROCEDURE
Intervention: catheter ablation of atrial fibrillation
Description: electric pulmonary vein disconnection

Intervention type: PROCEDURE
Intervention: catheter ablation of atrial fibrillation
Description: electric pulmonary vein disconnection

Intervention type: PROCEDURE
Intervention: catheter ablation of atrial fibrillation
Description: electric pulmonary vein disconnection

Intervention type: PROCEDURE
Intervention: catheter ablation of atrial fibrillation
Description: electric pulmonary vein disconnection

Intervention type: PROCEDURE
Intervention: catheter ablation of atrial fibrillation
Description: electric pulmonary vein disconnection
Study: NCT01353742

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine
Description: 100mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adefovir dipivoxil
Description: 10mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed dose combination (Lamivudine and Adefovir dipivoxil)
Description: 100mg/10mg capsule
Study: NCT00968851

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EVP-6124
Description: Arms: 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Arm: 3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EVP-6124
Description: Arms: 2
Study: NCT02937714

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: School Mental Health training
Description: School based intervention (Teacher training intervention) is the teachers training program based on World Health Organization, Eastern Mediterranean Region (WHO-EMRO) School mental health manual draft (December 2014). Topics to be covered in training workshop include normal childhood development, behaviour management strategies for schools, life skills training, essential components for healthy schools, recognizing warning signs for common psychiatric and developmental disorders common to children and adolescents \& school based interventions for various psychiatric problems
Study: NCT04870879

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver Transplant
Description: Liver Transplant from cadaveric donors

Intervention type: DRUG
Group type: OTHER
Intervention: Chemotherapy
Description: Chemotherapy
Study: NCT01479712

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline Irrigation
Description: Irrigation with warm normal saline into the abdominal cavity. Approximately 500-1000cc.
Study: NCT01056146

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based Interacting Together Everyday: Recovery After Childhood TBI
Description: Families in I-InTERACT will look through 10 web-sessions (like chapters) and participate in 10 family meetings focusing on education about traumatic brain injury, parenting skills, communication, behavior strategies, and stress management. Meetings will be conducted in their home using a computer hook-up with a trained therapist. Families will also be contacted two times per month by the counselor to discuss individual problems or concerns.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet Resources Comparison
Description: Families in the IRC group will receive computers, high speed internet access, and links to brain injury information and resources. The resources are available for families to access as often as they choose.
Study: NCT02566304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T Cell-Depleted Donor Lymphocyte Infusion
Description: Undergo DLI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo PBSC transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo PBSC transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Given IV
Study: NCT03743636

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotinamide riboside
Description: Participants randomized to the NR + resveratrol arm or the NR + placebo arm of the study will receive 1,000 mg of NR daily for six months.
Study: NCT02566304

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT00654862

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cocoa polyphenols
Description: Oral administration of capsules with 1000 mg polyphenols, 250 mg polyphenols or placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cocoa polyphenols
Description: Oral administration of capsules with 1000 mg polyphenols, 250 mg polyphenols or placebo
Study: NCT02670135

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triclosan Containing Toothpaste
Description: Active formula containing 0.3% triclosan in a1450 ppm sodium fluoride/silica base
Study: NCT03743636

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotinamide riboside
Description: Participants randomized to the NR + resveratrol arm or the NR + placebo arm of the study will receive 1,000 mg of NR daily for six months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Resveratrol
Description: Participants randomized to the NR + resveratrol arm of the study will receive 125 mg of resveratrol daily for six months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants randomized to the NR + placebo arm of the study will receiving placebo pills that are identical in appearance to resveratrol. Participants randomized to the placebo + placebo arm of the study will receive pills that are identical in appearance to NR and resveratrol. Participants will receive placebo pills daily for six months.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomized to the NR + placebo arm of the study will receiving placebo pills that are identical in appearance to resveratrol. Participants randomized to the placebo + placebo arm of the study will receive pills that are identical in appearance to NR and resveratrol. Participants will receive placebo pills daily for six months.
Study: NCT02670135

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Triclosan Free Toothpaste
Description: Control toothpaste with no triclosan ingredients in a 1450 ppm sodium fluoride/silica base - matching placebo
Study: NCT01283165

Intervention type: BEHAVIORAL
Intervention: Health education intervention
Description: Health education was conducted in two ways. (1) Teachers were taught how to use the flip chart that contained health education material about parasites. The lessons were done during free periods as this intervention had not been formally fitted into the school syllabus. (2) The research team provided health education to school children. Focus group discussions were conducted by the research team with school children all assembled outside their classes. Health education leaflets were distributed to all school children at the school. Children were asked to share the health information with their friends and families.
Study: NCT02386150

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RVEc
Description: The composition of the final drug product, prior to any dilution, is 0.2 mg recombinant ricin toxin 1-33/44-198 (RVEc) in buffer and 0.2% Alhydrogel® at a final volume of 1 mL per vial

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RVEc
Description: The composition of the final drug product, prior to any dilution, is 0.2 mg recombinant ricin toxin 1-33/44-198 (RVEc) in buffer and 0.2% Alhydrogel® at a final volume of 1 mL per vial
Study: NCT00986700

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: late night meal
Description: Three different kinds of late night meal each for 2 days.